Search

Displaying results 6011 - 6020 of 10000 in total
  1. Drug

    iCo-007

    go.drugbank.com/drugs/DB05268
    Investigational

    iCo-007 (formerly known as ISIS 13650) is a second generation antisense compound being developed by iCo for the treatment of various eye diseases caused by the formation of new blood vessels (angiogenesis

  2. Drug

    Echinacoside

    go.drugbank.com/drugs/DB15488
    Investigational

    [A184577] Echinacoside has demonstrated inhibition of apoptosis in neural cell lines, demonstrating potential for use in the treatment of neurological conditions.[A184592] … Echinacoside is a phenylethanoid glycoside isolated from _Echinacea angustifolia_ in 1950, and currently being investigated for the treatment of Parkinson's, Alzheimer's, atherosclerosis, osteoporosis,

  3. Drug

    NV-52

    go.drugbank.com/drugs/DB05673
    Experimental

    NV-52 is an investigational synthetic flavonoid thromboxane synthase (TXS) inhibitor developed for the maintenance of remission in inflammatory bowel disease.

  4. Drug

    Rexin G

    go.drugbank.com/drugs/DB16450
    Investigational

    Rexin-G is a tumor-targeted, injectable retroviral vector carrying a mutant form of the cyclin G1 gene. … It is under development by Epeius Biotechnologies for the potential treatment of metastatic cancer. It is also being investigated for preventing SARSCOV-2 viral entry.

    Synonyms: DeltaRex-G, Rexin GInternational brands: Rexin-G
  5. Drug

    MDX-1303

    go.drugbank.com/drugs/DB05945
    Investigational

    MDX-1303 is a fully human antibody against the inhalation anthrax, the most lethal form of illness in humans caused by the Bacillus anthracis bacterium, and targets a protein component of these lethal

  6. Drug

    Denibulin

    go.drugbank.com/drugs/DB05932
    Experimental

    Denibulin is a novel small molecule Vascular Disrupting Agent under development by MediciNova for treatment of solid tumor cancers.

  7. Drug

    PYM50018

    go.drugbank.com/drugs/DB05126
    Experimental

    When administered orally to a transgenic pre-clinical model of ALS, PYM50018 delays the loss of muscle strength and extends survival time. … It is developed for the treatment of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease).

  8. Drug

    Enzastaurin

    go.drugbank.com/drugs/DB06486
    Investigational

    Enzastaurin, an investigational, targeted, oral agent, will be evaluated at more than 100 sites worldwide for the treatment of relapsed glioblastoma multiforme (GBM), an aggressive and malignant form of

  9. Drug

    NS-3728

    go.drugbank.com/drugs/DB05835
    Experimental

    NS3728 is an orally active chloride channel blocker for the treatment of cancer.

  10. Drug

    XL820

    go.drugbank.com/drugs/DB05146
    Investigational

    XL820 exhibits dose-dependent growth inhibition in models of breast carcinoma, gliomas and leukemia. … PDGFR), mast/stem cell growth factor receptor KIT, vascular endothelial growth factor receptor 2, and platelet-derived growth factor receptor alpha, clinically validated targets implicated in a variety of